Jupiter Neurosciences (JUNS)
Market Price (3/30/2026): $0.3368 | Market Cap: $11.5 MilSector: Health Care | Industry: Biotechnology
Jupiter Neurosciences (JUNS)
Market Price (3/30/2026): $0.3368Market Cap: $11.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -155% | Penny stockMkt Price is 0.3 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 | ||
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.6 Mil | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -68% | ||
| High stock price volatilityVol 12M is 166% | ||
| Key risksJUNS key risks include [1] its heavy dependence on the success of a single drug candidate, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -155% |
| Penny stockMkt Price is 0.3 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.6 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -68% |
| High stock price volatilityVol 12M is 166% |
| Key risksJUNS key risks include [1] its heavy dependence on the success of a single drug candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Jupiter Neurosciences (JUNS) stock has lost about 70% since 11/30/2025 because of the following key factors:
1. Significant Share Dilution and Financing Structure.
Jupiter Neurosciences' stock faced downward pressure due to approved measures for substantial share dilution. On December 19, 2025, shareholders approved an amendment to increase authorized common shares from 125 million to 500 million. This also included the potential issuance of more than 19.99% of outstanding shares in connection with up to $20 million of securities issuable under a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., indicating a high risk of dilution to fund ongoing operations and clinical trials.
2. Lack of Product Revenue and Increasing Net Losses.
As of September 30, 2025 (Q3 2025), the company reported no revenue from product sales since its inception. For the nine months ending September 30, 2025, Jupiter Neurosciences reported a net loss of $6.07 million and an operating cash flow of -$3.05 million. The cash balance also significantly declined from $3.77 million at December 31, 2024, to $0.724 million by September 30, 2025, highlighting a lack of near-term revenue generation to offset operational costs.
Show more
1. Significant Share Dilution and Financing Structure.
Jupiter Neurosciences' stock faced downward pressure due to approved measures for substantial share dilution. On December 19, 2025, shareholders approved an amendment to increase authorized common shares from 125 million to 500 million. This also included the potential issuance of more than 19.99% of outstanding shares in connection with up to $20 million of securities issuable under a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., indicating a high risk of dilution to fund ongoing operations and clinical trials.
2. Lack of Product Revenue and Increasing Net Losses.
As of September 30, 2025 (Q3 2025), the company reported no revenue from product sales since its inception. For the nine months ending September 30, 2025, Jupiter Neurosciences reported a net loss of $6.07 million and an operating cash flow of -$3.05 million. The cash balance also significantly declined from $3.77 million at December 31, 2024, to $0.724 million by September 30, 2025, highlighting a lack of near-term revenue generation to offset operational costs.
Show more
Stock Movement Drivers
Fundamental Drivers
The -71.4% change in JUNS stock from 11/30/2025 to 3/29/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.23 | 0.35 | -71.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 34 | 34 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| JUNS | -71.4% | |
| Market (SPY) | -5.3% | 11.1% |
| Sector (XLV) | -8.7% | 7.2% |
Fundamental Drivers
The -76.2% change in JUNS stock from 8/31/2025 to 3/29/2026 was primarily driven by a -2.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.47 | 0.35 | -76.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 33 | 34 | -2.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| JUNS | -76.2% | |
| Market (SPY) | 0.6% | 18.7% |
| Sector (XLV) | 5.2% | 10.1% |
Fundamental Drivers
The -46.2% change in JUNS stock from 2/28/2025 to 3/29/2026 was primarily driven by a -22.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.65 | 0.35 | -46.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 26 | 34 | -22.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| JUNS | -46.2% | |
| Market (SPY) | 9.8% | 0.8% |
| Sector (XLV) | -2.1% | 2.2% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| JUNS | ||
| Market (SPY) | 69.4% | 1.1% |
| Sector (XLV) | 18.4% | -2.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| JUNS Return | - | - | - | 95% | -90% | -66% | -94% |
| Peers Return | 27% | -66% | 52% | 12% | -16% | -18% | -49% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| JUNS Win Rate | - | - | - | 100% | 50% | 33% | |
| Peers Win Rate | 55% | 30% | 47% | 50% | 43% | 27% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| JUNS Max Drawdown | - | - | - | 0% | -95% | -66% | |
| Peers Max Drawdown | -40% | -78% | -28% | -37% | -61% | -35% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: DNLI, AVXL, LRMR, BHVN, QNCX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
JUNS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to DNLI, AVXL, LRMR, BHVN, QNCX
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Jupiter Neurosciences (JUNS)
Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company incorporated in Delaware in January 2016. The Company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. The product candidate, called JOTROL™, has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS and with ALS in an earlier development stage. In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimer’s disease with an early development program in TBI/concussions. We believe that a high dose of resveratrol is needed for therapeutic effects. Currently available resveratrol products are associated with severe gastrointestinal (GI) side effects at the dose levels we believe are needed. Our belief is based on available scientific literature, preclinical trial results conducted in mice and rats, and previously conducted human trials with resveratrol. We believe that JOTROL™, based on the results from our Phase I trial, see section “Description of Business”, has the potential to deliver a therapeutically effective dose of resveratrol in the blood stream without causing gastrointestinal (GI) side effects. Based on our pre-clinical and Phase I study results, we expect that JOTROLTM will resolve “the major obstacle of resveratrol’s poor bioavailability” as discussed in AY Berman’s summary article in the Journal of Precision Oncology (AY Berman, 2017). Based on our own preclinical studies we believe that resveratrol has the ability to cross the blood-brain. In studies conducted in Friedreich’s ataxia (FA) and Alzheimer’s disease (AD) patients, resulted in positive effects on oxidative stress, inflammation, and mitochondrial function. The FA study was concluded in Australia by Murdoch Children’s Research Institute in 2015 (Yiu et al.). The AD study was conducted in 2015 by the Alzheimer’s Disease Cooperative Study with Professor Raymond Turner, MD, Ph.D., Georgetown, as principal investigator (Turner et al.). Both studies have been published in scientific journals and further described in the section “Description of Business”. In 2020, we received approval for full funding, $1.76 million, for our Phase I study from the National Institute on Aging (“NIA”). We plan to continue pursuing grant funding opportunities in all areas where they are available, such as Phase II and Phase III trials in Alzheimer’s disease as well as any funding available for our rare disease projects. In the NIA scientific review summary statement of our Phase I study application, it is stated that NIA is looking forward to a Phase II study with an enhanced resveratrol product, based on the earlier study results from the well published Turner et al. Alzheimer’s study. We recently submitted a grant application to NIA for full funding, including corporate overhead for a total of $18.3 million, for the duration of the study, of a Phase II trial in Mild Cognitive Impairment (MCI) and early Alzheimer’s disease. There is however no guarantee that this and future grant applications will be successful and therefore the rejection of our future grant application may significantly delay the Company’s plans in connection with MCI and Alzheimer’s and may have a significant impact on the Company’s financial performance. Further, the Company may never receive any future grants or costs savings. Since inception, we have operated with limited human capital, utilizing agreements with academia to get pre-clinical work executed at no cost, negotiating favorable deals for data already produced for resveratrol (e.g. toxicity studies and Phase II clinical study data), obtaining a full grant from NIA for our first clinical trial and building a management and scientific consulting team (consisting of the Scientific Advisory Board and business advisors) primarily compensated with equity securities of the company. We believe that this compensation method aligns the management, Scientific Advisory Board members and business advisors’ interests with the shareholders. We believe that our structure with a core management team that has experience in the utilization of outside resources makes it possible for us to efficiently execute several programs simultaneously in a cost-effective way. For the fiscal years ended December 31, 2020 and 2019, we generated no revenues from product sales and reported net losses of $1,654,699 and $3,046,719, respectively, and negative cash flow from operating activities of $254,783 and $142,952, respectively. For the nine months ended September 30, 2021 and 2020, we generated no revenues from product sales and reported net losses of $2,293,756 and $1,190,329, respectively, and negative cash flow from operating activities of $590,736 and $413,226, respectively. We are currently incorporated and in good standing in the State of Delaware. Our principal executive offices are located at 1001 North US Hwy 1, Suite 504, Jupiter, Florida.
AI Analysis | Feedback
Here are 1-2 brief analogies for Jupiter Neurosciences (JUNS):
- Moderna for Resveratrol's Brain Delivery: Jupiter Neurosciences is like a specialized biotech company, similar to how Moderna developed a platform for mRNA delivery, but focused on engineering a superior delivery system for resveratrol to make it an effective treatment for neurological and neuro-inflammatory diseases.
- An Early Biogen for Resveratrol: Think of them as an early-stage biotech company (like a nascent Biogen, known for neurological disorders) but uniquely focused on unlocking the full therapeutic potential of resveratrol for conditions like Alzheimer's and rare neuro diseases by solving its critical bioavailability and delivery challenges.
AI Analysis | Feedback
- JOTROL™: A unique resveratrol platform product designed to deliver therapeutically effective doses of resveratrol for the treatment of neuro-inflammation, rare diseases (such as Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, MELAS, ALS), and larger disease areas like Mild Cognitive Impairment/early Alzheimer’s disease, without causing gastrointestinal side effects.
AI Analysis | Feedback
```htmlJupiter Neurosciences (JUNS) is a clinical-stage research and development pharmaceutical company. According to the provided background information, the company has generated no revenues from product sales for the fiscal years ended December 31, 2020 and 2019, nor for the nine months ended September 30, 2021 and 2020.
Therefore, Jupiter Neurosciences currently does not have any major customers, as it is still in the development phase and has not yet brought a product to market.
```AI Analysis | Feedback
nullAI Analysis | Feedback
Christer Rosén, Founder, Chairman & CEO
Christer Rosén is the primary founder and Chairman & CEO of Jupiter Neurosciences, Inc. Originally from Halmstad, Sweden, he started his first company, a discotheque, at age 17. After college, he founded a software consulting company and was involved in the entertainment business, including restaurants and a hotel. From 1997 through May 2015, he founded and served as the Chief Executive Officer and Chairman of EffRx Pharmaceuticals. At EffRx, he co-invented and developed Binosto®, an osteoporosis drug that received FDA and EU approvals and is now distributed in several countries worldwide.
Saleem Elmasri, CPA, CFO
Saleem Elmasri has served as Chief Financial Officer since January 2023. Since September 2020, he has been a Principal at Titan Advisory Services LLC, a boutique advisory firm providing financial operations and CFO services to early-stage companies. Mr. Elmasri was a Managing Director at DLA LLC, a professional services firm, from June 2019 to April 2021. He began his career at PricewaterhouseCoopers, where he worked on Fortune 500 clients, primarily in the Life Sciences and Pharmaceutical industry. He has over 15 years of experience in financial and management consulting.
Marshall Hayward, Ph.D., Co-Founder, CSO
Marshall Hayward is the Chief Scientific Officer at Jupiter Neurosciences, Inc. Between 2002 and 2013, Dr. Hayward served as Chief Scientific Officer at Effrx Pharmaceuticals, where he played a key role in the development and approval of the Binosto® product. He also held positions as Vice President of Business Development for Hurley Consulting Associates, LTD., Director of New Business Development at Rhoda Pharmaceutical Ingredients, and Director and Vice President of Analgesics Research and Development at SmithKline Beecham (UK). He is a co-inventor of Jupiter Neurosciences' proprietary technology.
Alexander Rosén, Co-Founder, CAO
Alexander Rosén is a Co-Founder and Chief Administrative Officer at Jupiter Neurosciences, Inc. (formerly Jupiter Orphan Therapeutics, Inc.), having been with the company since its inception. From February 2019 to July 2021, Mr. Rosén worked part-time as Controller and Head of Administration & Office Management at X-VAX Technology, Inc. Before his corporate career, he was a professional golfer, playing on various tours across North America and Europe.
Alison D. Silva, President & CBO
Alison D. Silva serves as President & Chief Business Officer. Previously, she was the Chief Executive Officer of Cotinga Pharmaceuticals (formerly Critical Outcome Technologies) from July 2016 through August 2021. In 2013, she co-founded The Microbiome Company, later rebranded to Synlogic Therapeutics, where she served as Executive Vice President and Chief Operating Officer until June 2016. Her other relevant experience in biotech and pharma includes co-founder and Vice President of Development at Marina Biotech, and co-founder and Director at The Orphan Group.
AI Analysis | Feedback
- Significant Dependence on Grant Funding for Operations and Development: Jupiter Neurosciences explicitly relies on grant funding, particularly from the National Institute on Aging (NIA), to finance its crucial clinical trials, including a recently submitted application for an $18.3 million Phase II trial in Mild Cognitive Impairment and early Alzheimer’s disease. The company states that "rejection of our future grant application may significantly delay the Company’s plans in connection with MCI and Alzheimer’s and may have a significant impact on the Company’s financial performance" and that "the Company may never receive any future grants or costs savings." This reliance on external, non-guaranteed funding poses a substantial risk to its ability to advance its product pipeline and sustain operations.
- High Risk of Clinical Trial Failure for its Sole Product Candidate, JOTROL™: As a clinical-stage pharmaceutical company, Jupiter Neurosciences' future is entirely dependent on the successful, costly, and lengthy progression of its lead product candidate, JOTROL™, through Phase II, Phase III, and subsequent regulatory approval. While Phase I results are reported as positive, a significant majority of drug candidates fail in later-stage trials due to lack of efficacy, safety concerns, or other unforeseen issues. Failure at any of these advanced stages would lead to a complete loss of investment in JOTROL™ and would severely impact the company's viability, given its focus on a single platform.
AI Analysis | Feedback
nullAI Analysis | Feedback
Jupiter Neurosciences (JUNS) is developing JOTROL™ to target several neurological conditions. The estimated addressable markets for these conditions are as follows:
- Mucopolysaccharidoses Type 1 (MPS I): The global mucopolysaccharidosis treatment market, which includes MPS I, was valued at USD 4.19 billion in 2025 and is predicted to reach approximately USD 11.49 billion by 2035. The MPS I segment held the largest share of the global market in 2025. Specifically for MPS I, the market size in the 7MM (United States, Germany, France, Italy, Spain, United Kingdom, and Japan) was approximately USD 145 million in 2024 and is projected to grow to USD 297 million in 2034. The U.S. market for MPS I was around USD 70 million in 2024.
- Friedreich's Ataxia (FA): The global Friedreich's Ataxia market size was estimated at USD 2.63 billion in 2024 and is expected to reach USD 3.59 billion by 2032. Another estimate places the global market at USD 1.12 billion in 2025, expected to reach USD 2.07 billion by 2030. North America held the largest revenue share, accounting for 41.5% in 2024.
- MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes): The market for MELAS syndrome across the top 7 major markets (US, EU4, UK, and Japan) reached a value of USD 170.5 million in 2024 and is expected to reach USD 512.2 million by 2035. The United States is noted as having the largest patient pool and representing the largest market for MELAS treatment.
- ALS (Amyotrophic Lateral Sclerosis): The global market for amyotrophic lateral sclerosis treatments was valued at USD 713.3 million in 2023 and is projected to grow to USD 1,271.6 million by 2033. Another report valued the global ALS treatment market at USD 752.0 million in 2024, poised to grow to USD 1,238.49 million by 2033. North America dominated the global market with a revenue share of 37.7% in 2023.
- Mild Cognitive Impairment (MCI) and early Alzheimer's disease (AD): The global Mild Cognitive Impairment market size was valued at USD 2.1 billion in 2022 and is expected to reach USD 3.5 billion by 2032. It was over USD 2.51 billion in 2025 and is anticipated to cross USD 4.29 billion by 2035. North America is the largest region in the MCI market, projected to hold a 45.4% share by 2035. For Alzheimer's disease, the global market was USD 5.10 billion in 2022 and is likely to reach USD 9.73 billion by 2030. The Alzheimer's disease diagnostics and treatment market is projected to rise from US$ 7.72 billion in 2025 to US$ 14.14 billion by 2032 globally. The Alzheimer's disease market in the 7MM (US, EU4, UK, Japan) is valued at approximately USD 5,048 million in 2025 and is projected to grow to USD 34,335 million by 2034. The U.S. accounted for approximately 54% of the total Alzheimer's disease market size in 7MM in 2023.
- TBI/Concussions: The global concussion market size was estimated at USD 6.58 billion in 2024 and is projected to reach USD 9.31 billion by 2030. Another source reported the global concussion market size at USD 8.2 billion in 2025, growing to USD 8.58 billion in 2026, and expected to reach USD 10.43 billion in 2030. The Traumatic Brain Injuries Assessment Market size was over USD 11.66 billion in 2025 and is poised to exceed USD 24.03 billion by 2035 globally. North America was the largest region in the concussion market in 2024, holding a 60.9% revenue share, and holds a 47.5% share in the traumatic brain injuries assessment market.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Jupiter Neurosciences (JUNS)
- Strategic Partnerships and Licensing Agreements for JOTROL™: As a clinical-stage company with a novel resveratrol platform, Jupiter Neurosciences is well-positioned to attract strategic partnerships or licensing agreements for its lead product candidate, JOTROL™. These agreements, potentially covering co-development, commercialization rights, or regional licenses for indications such as Mild Cognitive Impairment/early Alzheimer's disease or various rare diseases, could generate significant upfront payments and development milestone payments, which would constitute revenue growth. The company's lean operating model and reliance on external resources suggest an openness to such collaborations as a path to market.
- Commercialization of JOTROL™ in Rare Disease Indications: Jupiter Neurosciences is targeting several rare diseases, including Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS. Due to the potential for expedited regulatory pathways and orphan drug designations often associated with rare diseases, successful and rapid clinical development could lead to accelerated approval and initial product sales for JOTROL™ within the next 2-3 years, contributing to revenue growth.
- Achievement of Key Clinical Development Milestones for JOTROL™ in Mild Cognitive Impairment (MCI) and early Alzheimer’s disease: The company has identified MCI and early Alzheimer’s disease as a primary target in larger disease areas and has applied for significant grant funding for a Phase II trial. Positive results from such pivotal trials would substantially de-risk JOTROL™. While direct product sales in this large market are unlikely within a 2-3 year timeframe, successful advancement through these clinical stages would likely trigger significant milestone payments from existing or future strategic partnerships, or could increase the company's attractiveness for acquisition, leading to revenue generation.
AI Analysis | Feedback
Share Issuance
- Management, Scientific Advisory Board members, and business advisors are primarily compensated with equity securities of the company.
Inbound Investments
- The company received $1.76 million in full funding from the National Institute on Aging (NIA) in 2020 for its Phase I study.
- A grant application for $18.3 million for full funding, including corporate overhead, was recently submitted to NIA for a Phase II trial in Mild Cognitive Impairment (MCI) and early Alzheimer’s disease.
Trade Ideas
Select ideas related to JUNS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 3.72 |
| Mkt Cap | 0.3 |
| Rev LTM | 0 |
| Op Inc LTM | -109 |
| FCF LTM | -76 |
| FCF 3Y Avg | -53 |
| CFO LTM | -76 |
| CFO 3Y Avg | -53 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | - |
| Rev Chg 3Y Avg | - |
| Rev Chg Q | - |
| QoQ Delta Rev Chg LTM | - |
| Op Mgn LTM | - |
| Op Mgn 3Y Avg | - |
| QoQ Delta Op Mgn LTM | - |
| CFO/Rev LTM | - |
| CFO/Rev 3Y Avg | - |
| FCF/Rev LTM | - |
| FCF/Rev 3Y Avg | - |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.3 |
| P/S | - |
| P/EBIT | -1.9 |
| P/E | -2.0 |
| P/CFO | -2.6 |
| Total Yield | -52.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -23.4% |
| D/E | 0.0 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -28.8% |
| 3M Rtn | -23.7% |
| 6M Rtn | -55.8% |
| 12M Rtn | -58.8% |
| 3Y Rtn | -52.5% |
| 1M Excs Rtn | -23.0% |
| 3M Excs Rtn | -15.3% |
| 6M Excs Rtn | -49.6% |
| 12M Excs Rtn | -73.1% |
| 3Y Excs Rtn | -112.9% |
Price Behavior
Price Behavior
| Market Price | $0.35 | |
| Market Cap ($ Bil) | 0.0 | |
| Distance from 52W High | -88.2% | |
| 50 Days | 200 Days | |
| DMA Price | $0.56 | $3.14 |
| DMA Trend | down | down |
| Distance from DMA | -37.0% | -88.9% |
| 3M | 1YR | |
| Volatility | 105.7% | 166.4% |
| Downside Capture | 3.31 | 0.42 |
| Upside Capture | -0.94 | -24.71 |
| Correlation (SPY) | 10.7% | 0.8% |
JUNS Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.23 | 1.22 | 1.25 | 1.72 | 0.01 | 0.45 |
| Up Beta | -1.45 | 0.96 | 1.04 | 1.22 | -0.10 | 2.09 |
| Down Beta | -4.37 | -5.73 | -3.53 | -0.26 | 0.75 | -0.44 |
| Up Capture | 284% | 166% | 91% | 99% | -17% | -6% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 6 | 13 | 19 | 48 | 107 | 129 |
| Down Capture | 404% | 561% | 445% | 283% | -21% | 58% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 15 | 28 | 39 | 69 | 134 | 167 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with JUNS | |
|---|---|---|---|---|
| JUNS | -62.3% | 164.7% | 0.08 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 2.5% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 1.4% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 1.1% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 2.9% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 1.6% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 5.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with JUNS | |
|---|---|---|---|---|
| JUNS | -44.7% | 176.1% | -0.47 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | -1.8% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 1.5% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 1.8% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 4.2% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | -1.6% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 3.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with JUNS | |
|---|---|---|---|---|
| JUNS | -25.7% | 176.1% | -0.47 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | -1.8% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 1.5% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 1.8% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 4.2% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | -1.6% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 3.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/19/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/28/2025 | 10-K |
| 09/30/2024 | 12/23/2024 | 10-Q |
| 06/30/2024 | 12/02/2024 | 424B3 |
| 03/31/2024 | 07/12/2024 | S-1/A |
| 09/30/2022 | 12/02/2022 | S-1/A |
| 06/30/2022 | 08/26/2022 | S-1/A |
| 03/31/2022 | 05/18/2022 | S-1/A |
| 09/30/2021 | 02/03/2022 | S-1/A |
| 06/30/2021 | 11/09/2021 | S-1/A |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Silva, Alison D | Pres + Chief Business Officer | Direct | Buy | 7032025 | 1.03 | 750 | 772 | 116,123 | Form |
| 2 | Rosen, Christer | CEO and Chairman | Direct | Buy | 7032025 | 1.02 | 3,600 | 3,667 | 11,285,082 | Form |
| 3 | Silva, Alison D | Pres + Chief Business Officer | Direct | Buy | 7012025 | 1.03 | 850 | 877 | 114,589 | Form |
| 4 | Silva, Alison D | Pres + Chief Business Officer | Direct | Buy | 7012025 | 1.03 | 950 | 978 | 115,369 | Form |
| 5 | Rosen, Christer | CEO and Chairman | Direct | Buy | 7012025 | 1.06 | 166 | 176 | 11,731,701 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.